𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A randomized, placebo-controlled, double-blind trial of mesalamine in the maintenance of remission of Crohn's disease. The Canadian Mesalamine for Remission of Crohn's Disease Study Group

✍ Scribed by LR Sutherland; F Martin; RJ Bailey; RN Fedorak; M Poleski; C Dallaire; R Rossman; F Saibil; L Lariviere

Book ID
118519812
Publisher
Elsevier Science
Year
1997
Tongue
English
Weight
345 KB
Volume
112
Category
Article
ISSN
0016-5085

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

A randomized, double-blind, placebo-cont
A randomized, double-blind, placebo-controlled trial of olsalazine for active Crohn's disease
✍ J. P. Wright; Dr. D. P. Jewell; R. Modigliani; H. Malchow πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 486 KB πŸ‘ 2 views

Olsalazine, consisting of two salicylate radicals linked by an azo-bond, is effective in the treatment of active ulcerative colitis. To test its effect in patients with mild to moderate attacks of Crohn's disease, the International Organization for the Study of Inflammatory Bowel Disease (IOIBD) des

Randomized, placebo-controlled, double-b
Randomized, placebo-controlled, double-blind trial of Boswellia serrata in maintaining remission of Crohn's disease: Good safety profile but lack of efficacy
✍ Wolfgang Holtmeier; Stefan Zeuzem; Jan PreiΞ²; Wolfgang Kruis; Stephan BΓΆhm; Chri πŸ“‚ Article πŸ“… 2011 πŸ› John Wiley and Sons 🌐 English βš– 425 KB πŸ‘ 2 views

Background: Complementary therapies are frequently used by patients with inflammatory bowel disease (IBD). The aim of this study was to evaluate the efficacy and safety of long-term therapy with a new Boswellia serrata extract (Boswelan, PS0201Bo) in maintaining remission in patients with Crohn's di